Cannabinoid receptor expression profiling in lymphocyte subsets reveals clinically relevant immune patterns in SLE.

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with complex immune dysregulation.
• Cannabinoid receptors (CB1R and CB2R) play roles in immune modulation.
• Understanding cannabinoid receptor expression in SLE is crucial for identifying new therapeutic strategies.

Purpose of the Study:

• To investigate the expression levels of cannabinoid receptors 1 (CB1R) and 2 (CB2R) in lymphocytes of SLE patients compared to healthy controls.
• To determine the association between cannabinoid receptor expression and SLE disease activity.

Main Methods:

• Peripheral blood mononuclear cells were isolated from 35 SLE patients and 35 healthy controls.
• Multiparametric flow cytometry was utilized to analyze T-cell and B-cell subpopulations.
• Expression levels of CB1R and CB2R were quantified in different lymphocyte subsets.

Main Results:

• SLE patients showed significantly higher CB2R and lower CB1R expression compared to controls.
• CB1R expression levels correlated with SLE disease activity.
• CB2R expression in B-cell subsets differentiated between active disease and remission, with significant diagnostic accuracy in ROC analysis.

Conclusions:

• SLE is characterized by distinct alterations in lymphocyte cannabinoid receptor profiles.
• CB1R and CB2R represent potential biomarkers for SLE disease activity and progression.
• Modulation of CB1R and CB2R may offer novel therapeutic avenues for SLE management.